Boston Scientific (BSX) Short term Debt (2009 - 2026)

Boston Scientific has disclosed Short term Debt across 18 years of filings, most recently posting $1.7 billion for Q2 2026.

• In Q2 2026, Short term Debt rose 256.04% year-over-year to $1.7 billion; the TTM figure through Jun 2026 stood at $1.7 billion (up 256.04% YoY), while the FY2025 annual figure was $299.0 million, down 83.18% from the prior year.
• Short term Debt came in at $1.7 billion for Q2 2026 at Boston Scientific, up from $41.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $1.8 billion in Q4 2024 to a low of $20.0 million in Q3 2022.
• Average Short term Debt over 5 years is $691.4 million, with a median of $511.5 million recorded in 2023.
• Year-over-year, Short term Debt soared 2555.0% in 2023 and tumbled 94.72% in 2026.
• Over 5 years, Short term Debt stood at $20.0 million in 2022, then soared by 2555.0% to $531.0 million in 2023, then surged by 234.84% to $1.8 billion in 2024, then tumbled by 83.18% to $299.0 million in 2025, then soared by 471.57% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $1.7 billion in Q2 2026, $41.0 million in Q1 2026, and $299.0 million in Q4 2025.